Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series
Background: Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods: This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023-May 2024). Results: Patients were heavily pretreated (median 4.5 prior lines; 5/10 post-CAR-T). After a median of five cycles, responses were observed in 7/9 evaluable patients, including complete response in 4/9. Cytokine-release syndrome occurred in 7/10 (mostly Grade 1-2), including grade 3 events in 2/10, while ICANS occurred in 2/10 patients, including one Grade 4 event. Three patients received glofitamab as bridging therapy and all proceeded to CAR-T infusion. Conclusion: Glofitamab showed encouraging activity and manageable toxicity in heavily pretreated MCL, including as bridging therapy to CAR-T-cell treatment. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Authors
- Teresa Magnes (ORCID: https://orcid.org/0000-0002-0618-6040)
- Emine Kaynak (ORCID: https://orcid.org/0000-0001-9850-2532)
- Michael Leisch
- Richard Greil (ORCID: https://orcid.org/0000-0002-4462-3694)
- Ferdinand Haslbauer (ORCID: https://orcid.org/0000-0002-1635-3260)
- Veronika Buxhofer‐Ausch (ORCID: https://orcid.org/0000-0002-7369-9700)
- Beatrice Casadei (ORCID: https://orcid.org/0000-0002-4453-6064)
- Thomas Melchardt (ORCID: https://orcid.org/0000-0002-0122-3631)
- Pier Luigi Zinzani (ORCID: https://orcid.org/0000-0002-2112-2651)
- Felix Keil (ORCID: https://orcid.org/0000-0002-0348-1677)
- Holger Rumpold
- Natalia Rotter
- Alexander Egle
- Agnes List
- Olga Saini
- Markus Raderer
- Georg Hess
Institutions
- Johannes Gutenberg University Mainz (DE)
- Paracelsus Medical University (AT)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Hanusch Hospital (AT)
- Istituto di Ematologia di Bologna (IT)
- Azienda USL di Bologna (IT)
- Tirol Kliniken (AT)
- Krankenhaus der Elisabethinen (AT)
- Austrian Breast & Colorectal Cancer Study Group (AT)
- Medical University of Vienna (AT)
- University of Bologna (IT)
Publication Details
- Journal
- eJHaem
- Published
- 2026-07-16
- DOI
- https://doi.org/10.1002/jha2.70343
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00